These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21402293)

  • 1. Health care use and primary prophylaxis with colony-stimulating factors.
    Sullivan SD; Ramsey SD; Blough DK; McDermott CL; Clarke L; McCune JS
    Value Health; 2011; 14(2):247-52. PubMed ID: 21402293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.
    McCune JS; Sullivan SD; Blough DK; Clarke L; McDermott C; Malin J; Ramsey S
    Pharmacotherapy; 2012 Jan; 32(1):7-19. PubMed ID: 22392824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer.
    Rajan SS; Lyman GH; Carpenter WR; Stearns SC
    Breast Cancer Res Treat; 2011 Jun; 127(2):511-20. PubMed ID: 20976544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.
    Wang L; Barron R; Baser O; Langeberg WJ; Dale DC
    Value Health; 2014 Sep; 17(6):739-43. PubMed ID: 25236998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
    Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
    Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
    Daniel DB; Crawford J;
    Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
    Heuser M; Ganser A; Bokemeyer C; ; ;
    Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment in oncology clinical practice. From risk factors to risk models.
    Lyman GH
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):8-13. PubMed ID: 14682113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
    Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    J Am Geriatr Soc; 2010 Oct; 58(10):1885-95. PubMed ID: 20840455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017.
    Schenfeld JR; Bennett CW; Li S; DeCosta LJ; Jaramillo RR; Gawade PL
    J Oncol Pharm Pract; 2021 Jan; 27(1):128-142. PubMed ID: 32326872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.
    Saloustros E; Tryfonidis K; Georgoulias V
    Expert Opin Pharmacother; 2011 Apr; 12(6):851-63. PubMed ID: 21254862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
    Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of primary prophylaxis on febrile neutropenia within community practices in the US.
    Hershman D; Hurley D; Wong M; Morrison VA; Malin JL
    J Med Econ; 2009 Sep; 12(3):203-10. PubMed ID: 19723018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.